Prognostic significance of cyclooxygenase-2 in osteosarcoma: a meta-analysis.
Jiao G, Ren T, Lu Q, Sun Y, Lou Z, Peng X, Liang W, Guo W · Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
Sarcoma subtypes
Abstract
Published studies researching the prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with osteosarcoma are inconclusive and heterogeneous. We conducted a meta-analysis to assess its prognostic value more precisely. The pooled odds ratios (ORs) or hazard ratios (HRs) with corresponding 95 % confidence intervals (CIs) were calculated to evaluate the effects. Fourteen studies with 735 osteosarcoma patients were included to estimate the relationship between COX-2 and metastasis of tumor, clinical stage, and 3-year overall survival. High expressions of COX-2 predicted neoplasm metastasis (OR = 1.891, 95 % CI 1.276-2.803, P = 0.002), advanced clinical stage (OR = 1.801, 95 % CI 1.257-2.581, P = 0.001). In addition, high COX-2 expression tended to be associated with a poor 3-year survival (HR = 1.741, 95 % CI 0.762-3.979, P = 0.188), but the difference was not significant. Therefore, this meta-analysis demonstrated that high COX-2 expression might be an unfavorable prognostic effect in osteosarcoma.
Shown exactly as published on PubMed. Your oncologist is the right person to judge whether these findings apply to your situation.
Publication type
Source: PubMed, PMID 23857285. Always confirm details with the original publication or your oncologist.